Agios (AGIO)
Biotech
Close on Nov 10, 2026 (from our latest Long View update): $31.76
- Market value
- $1.9Bat the Nov 10 close
- Revenue growth
- +214%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −239%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $907Mat Sep 30, 2026
- Worst fall since listing
- −87.4%Jan 14, 2015 to Jun 14, 2022; not back to that high (−78.7% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
Latest
The Long View
Agios sold its cancer business in 2021 to focus on rare blood diseases, then used the cash for a large buyback and its own launches.
▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash
Updated Nov 11, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for Agios, FY2011–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $22M in FY2011 to $54M in FY2025.
Free cash flow was positive in 1 of the 15 years shown; FY2025: −$377M.
Margins
Margins are not charted: in FY2025 the operating loss (−$472M) was larger than revenue ($54M). The table has each year's figures.
Diluted share count
The diluted share count fell 16% from FY2020 to FY2025, to 58M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $54M | — | −874% | −$413M | −$373M | $4M | −$377M |
| FY2024 | $36M | — | −1166% | $674M | −$390M | $2M | −$392M |
| FY2023 | $27M | — | −1460% | −$352M | −$296M | $1.0M | −$297M |
| FY2022 | $14M | — | −2732% | −$232M | −$309M | $5M | −$314M |
| FY2021 | $0 | — | — | $1.6B | −$407M | $6M | −$413M |
| FY2020 | $0 | — | — | −$327M | −$291M | $14M | −$305M |
| FY2019 | $118M | — | −268% | −$411M | −$371M | $12M | −$383M |
| FY2018 | $94M | — | −384% | −$346M | −$304M | $7M | −$311M |
| FY2017 | $43M | — | −746% | −$315M | −$285M | $5M | −$290M |
| FY2016 | $70M | — | −288% | −$198M | $39M | $10M | $29M |
| FY2015 | $59M | — | −201% | −$118M | −$77M | $20M | −$97M |
| FY2014 | $65M | — | −83% | −$54M | −$59M | $2M | −$62M |
| FY2013 | $26M | — | −152% | −$39M | −$56M | $1M | −$58M |
| FY2012 | $25M | — | −92% | −$20M | −$50M | $1M | −$51M |
| FY2011 | $22M | — | −76% | −$24M | −$15M | $2M | −$17M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 58M | $1.2B | — | $53M | — | — |
| FY2024 | 58M | $1.5B | — | $43M | — | — |
| FY2023 | 56M | $806M | — | $45M | — | $0 |
| FY2022 | 55M | $1.1B | — | $49M | — | $0 |
| FY2021 | 60M | $1.3B | $0.6M | $54M | — | $802M |
| FY2020 | 69M | $671M | $0.6M | $62M | — | $0 |
| FY2019 | 60M | $718M | $0.9M | $58M | — | $0 |
| FY2018 | — | $805M | — | $73M | — | — |
| FY2017 | — | $103M | — | $48M | — | — |
| FY2016 | — | $541M | — | $42M | — | — |
| FY2015 | — | $317M | — | $32M | — | — |
| FY2014 | — | $342M | — | $12M | — | — |
| FY2013 | — | $167M | — | $3M | — | — |
| FY2012 | — | $128M | — | $0.7M | — | — |
| FY2011 | — | $118M | — | $0.4M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 5, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | AGIO | S&P 500 |
|---|---|---|
| 2019 | +3.6% | +31.5% |
| 2020 | −9.3% | +18.4% |
| 2021 | −24.1% | +28.7% |
| 2022 | −14.6% | −18.1% |
| 2023 | −20.7% | +26.3% |
| 2024 | +47.5% | +25.0% |
| 2025 | −17.2% | +17.9% |
| 2026 to date | +5.7% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- NRIX Nurix Therapeutics Down 38.2%
- VERA Vera Down 1.2%
- XNCR Xencor Up 15.9%
- IMCR Immunocore Up 9.1%
- VKTX Viking Therapeutics
- ORIC ORIC Pharmaceuticals Down 32%
Show all 17
- SLS SELLAS Up 156.4%
- TNGX Tango Therapeutics Down 16.4%
- IOVA Iovance Down 35.4%
- ARWR Arrowhead Down 15.3%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about Agios
- How does Agios make money?
- Agios earns product revenue from mitapivat, an oral pyruvate kinase activator used to treat inherited anemias. In the US, it markets the drug as PYRUKYND for PK deficiency and AQVESME for thalassemia. Revenue was $54.0M in 2025. More in the Long View →
- What could drive Agios's growth?
- Agios's strategy combines expanding mitapivat into additional blood diseases, especially sickle cell disease, with developing other medicines. Its pipeline includes AG-236 for polycythemia vera, cevidoplenib for immune thrombocytopenia and AG-181 for phenylketonuria; these are investigational treatments. More in the Long View →
- Why does Agios's thalassemia drug need a safety program?
- In the US, AQVESME is restricted through a REMS because of liver-injury risk. The program requires regular liver testing, patient enrollment, and certified prescribers and pharmacies; PYRUKYND for PK deficiency does not require a REMS. More in the Long View →
- What are the main risks to Agios's business?
- Agios depends on mitapivat for product revenue. Its operations have consumed more cash than they generate, making funding its development and commercialization spending a central business risk. More in the Long View →
- How has Agios funded itself?
- Asset sales have been an important part of Agios's funding strategy: it sold its oncology business in 2021 and specified vorasidenib royalty rights in 2024. It also spent $802.5M on share repurchases in 2021. More in the Long View →
- What's coming up for Agios's pipeline in the next 12 months?
- Agios says the FDA's PDUFA goal date for mitapivat in sickle cell disease is February 1, 2027. By year-end 2026, Agios plans to start a Phase 2/3 program of AG-236 in polycythemia vera and expects Phase 1b proof-of-mechanism data for AG-181 in patients with phenylketonuria. As of Nov 5, 2026 More in the Long View →